抗癌免疫反应受到抑制检查点SIRPα的cis相互作用的阻碍
Zhenghai Tang1,2,3, Ming-Chao Zhong1, Jin Qian1
1Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Canada.
Science immunology
|October 10, 2025
概括
信号调节蛋白α (SIRPα) 通过CD47.7限制抗瘤活性. 新的研究表明,SIRPα还通过在cis中结合CD18来抑制巨细胞,从而阻断细胞化. 联合封锁可以增强免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 信号调节蛋白α (SIRPα) 是一种巨受体,通过与CD47在瘤细胞上的相互作用来抑制细胞和抗瘤反应.
- 这种相互作用是癌症免疫疗法的关键目标,旨在增强巨细胞介导的瘤细胞杀伤.
研究的目的:
- 调查SIRPα抑制巨细胞功能的机制,独立于CD47.
- 探索SIRPα的cis相互作用在调节巨细胞激活和细胞分裂中的作用.
主要方法:
- 利用生物化学分析和基于细胞的实验来研究SIRPα相互作用.
- 研究了SIRPα-CD18 cis相互作用对巨细胞激活和细胞发生的功能后果.
- 在临床前癌症模型中评估了SIRPα-CD18和SIRPα-CD47联合阻断的疗效.
主要成果:
- 鉴定出SIRPα在巨细胞上与CD18 (β2整合素) 的cis相互作用中介的CD47独立的抑制功能.
- 证明这种cis相互作用阻止了CD18激活,这是细胞分裂的关键步骤.
- 表明SIRPα-CD18和SIRPα-CD47相互作用的同时阻断是最大限度地促进细胞化和抑制瘤生长的必要条件.
结论:
- SIRPα采用双重机制来抑制巨细胞激活:与CD47的跨相互作用和与CD18的cis相互作用.
- 针对SIRPα的cis和trans抑制功能对于有效的免疫疗法至关重要.
- 这种双重作用模式提供了一个新的治疗策略,通过克服巨细胞抑制来增强癌症免疫疗法.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Experimental RNAi
7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


